The application for the market approval of the drug for hereditary angioedema by Jett Berlin in China has been accepted.

On July 18th, Interface News learned from Jet BioLin that the market application for its innovative drug FXIIa inhibitor monoclonal antibody has officially been accepted by the National Medical Products Administration Drug Evaluation Center for the prevention of hereditary angioedema attacks. Hereditary angioedema is a rare, life-threatening genetic disease characterized by recurrent and unpredictable skin and/or mucosal swelling. Garadacimab is the world's first and currently the only drug targeting factor XIIa for the prophylactic treatment of HAE. The drug has been granted marketing authorization in countries and regions such as the United States, the European Union, the United Kingdom, Japan, Australia, Switzerland, and the United Arab Emirates.